Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADJUVACCINE

Financiado

Development of a marketable adjuvant candidate for vaccine applications

ADJUVACCINE seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the scalable production of identified optimised saponin adjuvants for improved cost-effective... ver más

30/06/2024

ASOCIACION CENTRO...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ASOCIACION CENTRO DE INVESTIGACION COOPERATIV... Actividades de organizaciones profesionales asociacion

TRL 4-5 | 50K€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

ASOCIACION CENTRO DE INVESTI...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RYC-2015-17888 Synthesis and Conformational Analysis of Glycopeptides Incor... 309K€ Cerrado

ADJUPROBE LEAD ADJUVANT PROBE AS A DUAL TECHNOLOGICAL TOOL TO ADVANCE... 150K€ Cerrado

PDC2021-121884-I00 DESARROLLO DE UNA PLATAFORMA ADYUVANTE BASADA EN SAPONINAS S... 92K€ Cerrado

ADJU-PLATFORM MINIMAL SAPONIN-BASED ADJUVANT VACCINE PLATFORM 150K€ Cerrado

ADJUV-ANT VACCINES Elucidating the Molecular Mechanisms of Synthetic Saponin Ad... 1M€ Cerrado

PID2020-117911RB-I00 DISEÑO, SINTESIS, EVALUACION BIOLOGICA Y ESTUDIOS ESTRUCTURA... 145K€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2022-07-08
Fecha Fin: 2024-06-30

Líder del proyecto

ASOCIACION CENTRO DE INVESTIGACION COOPERATIV... Actividades de organizaciones profesionales asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 150K€

Descripción del proyecto ADJUVACCINE seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the scalable production of identified optimised saponin adjuvants for improved cost-effective vaccines. We have developed in the laboratory potent, safe, stable, and streamlined adjuvant leads that surpass the QS-21 natural product adjuvant, leading to patent applications and the interest of Pharma. In this PoC project, we aim to exploit our synthetic saponin technology to produce adjuvant/vaccine candidates at scale that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate the scalability of our innovative adjuvant technology and select an optimal adjuvant candidate in advanced preclinical settings for entering the vaccine market via spin-off formation following proper IPR strategy implementation and attraction of key investors/partners. The breakthrough innovation potential of ADJUVACCINE lies in the exploitation of this adjuvant platform for large-scale production and selection of the best candidate lead for application in vaccines against various diseases, improving the available vaccine solutions. The high purity and excellent chemical control of our synthetic technology versus the heterogeneous natural product adjuvants, as well as its streamlined, scalable nature and low-cost profile are unique attributes of our platform that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines. The main objectives are 1) demonstrate our synthetic technology platform for the gram-scale production and selection of a candidate adjuvant lead; and 2) implement valorisation opportunities and verify the potential of spin-off creation by establishing an optimal IPR and public/private funding roadmap plan.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores